TY - JOUR T1 - The allometric propagation of COVID-19 is explained by human travel JF - medRxiv DO - 10.1101/2021.04.08.21255169 SP - 2021.04.08.21255169 AU - Rohisha Tuladhar AU - Paolo Grigolini AU - Fidel Santamaria Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/13/2021.04.08.21255169.abstract N2 - We analyzed the number of cumulative positive cases of COVID-19 as a function of time in countries around the World. We tracked the increase in cases from the onset of the pandemic in each region for up to 150 days. We found that in 81 out of 146 regions the trajectory was described with a power-law function for up to 30 days. We also detected scale-free properties in the majority of sub-regions in Australia, Canada, China, and the United States (US). We developed an allometric model that was capable of fitting the initial phase of the pandemic and was the best predictor for the propagation of the illness for up to 100 days. We then determined that the power-law COVID-19 exponent correlated with measurements of human mobility. The COVID-19 exponent correlated with the magnitude of air passengers per country. This correlation persisted when we analyzed the number of air passengers per US states, an even per US metropolitan areas. Furthermore, the COVID-19 exponent correlated with the number of vehicle miles travelled in the US. Together, air and vehicular travel explained 70 % of the variability of the COVID-19 exponent. Taken together, our results suggest that the scale-free propagation of the virus is present at multiple geographical scales and is correlated with human mobility. We conclude that models of disease transmission should integrate scale-free dynamics as part of the modeling strategy and not only as an emergent phenomenological property.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPartial funding provided by NIMH-NIBIB 1R01EB026939Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB needed. The data analyzed was obtained from publicly available databases.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data was collected from publicly available databases. All analysis scripts are available upon request. ER -